Company profile
VICORE PHARMA HOLDING AB
NASDAQ:VCREBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BULOXIBUTID | phase3 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06588686 | phase2 | active_not_recruiting | 2024-12-09 | 2027-05-01 | Vicore Pharma AB | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
| NCT05831644 | phase1 | completed | 2023-03-31 | 2023-06-16 | Vicore Pharma AB | A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes |
| NCT05830799 | phase1 | completed | 2023-03-29 | 2023-05-11 | Vicore Pharma AB | A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers |
| NCT04880642 | phase3 | completed | 2021-09-16 | 2022-04-25 | Vicore Pharma AB | A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects |
| NCT04388176 | phase2 | completed | 2020-01-03 | 2020-12-14 | Vicore Pharma AB | Cold Challenge With C21 in RP |
FDA applications (0)
No records yet.